mRNA vaccine technology has been around for decades and offers many benefits over traditional vaccines. Here are the basics of how they work.
Gavin Harris, MD
Gavin Harris, MD
Emory University
Gavin Harris is an Assistant Professor of Medicine at Emory. He is trained in both infectious diseases and critical care medicine.
He completed undergraduate studies at Columbia University, attended medical school at SUNY Downstate Medical Center, and completed a residency and chief residency in internal medicine at Albert Einstein College of Medicine, all in NYC. He then undertook a dual clinical fellowship in infectious diseases and critical care medicine at the University of Pittsburgh.
Board certified in both internal medicine and infectious diseases, a fellow at the Johns Hopkins Center for Health Security in the Emerging Leaders in Biosecurity Initiative, he has professional interests in disaster medicine, biosecurity, and treatments of high consequence pathogens.
Recent Submissions
October 31, 2020
|
I Think I Have COVID-19
October 30, 2020
Monoclonal antibody therapy is an experimental treatment for COVID-19, and it may hold promise for those with mild disease.
September 11, 2020
|
Everyday Prevention
September 11, 2020
With three, soon-to-be four, vaccines entering Phase III (human) trials, we could see a successful vaccine very soon.
September 11, 2020
|
Everyday Prevention
September 11, 2020
Two more COVID-19 vaccines enter Phase III. One falters, but there’s still good reason for hope.
September 5, 2020
|
Everyday Prevention
September 5, 2020
Vaccines are crucial to defeating COVID-19, and they are undergoing rigorous testing at breakneck speeds to ensure safety and efficacy.
August 29, 2020
|
COVID-19 Basics
September 14, 2020
Cooler, drier air may help COVID-19 spread. And with people spending more time indoors, fall and winter could mean case numbers will rise.
July 27, 2020
|
COVID-19 Basics
July 29, 2020
Early data suggests that if given early to hospitalized patients, remdesivir may be of benefit for those with moderate to severe COVID-19.
End of content
No more pages to load
